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A B S T R A C T
Background
Celiac disease is a small intestine inflammatory disorder with multiple organ involvement,
sustained by an inappropriate immune response to dietary gluten. Anti-transglutaminase
antibodies are a typical serological marker in patients with active disease, and may disappear
during a gluten-free diet treatment. Involvement of infectious agents and innate immunity has
been suggested but never proven. Molecular mimicry is one of the mechanisms that links
infection and autoimmunity.
Methods and Findings
In our attempt to clarify the pathogenesis of celiac disease, we screened a random peptide
library with pooled sera of patients affected by active disease after a pre-screening with the
sera of the same patients on a gluten-free diet. We identified a peptide recognized by serum
immunoglobulins of patients with active disease, but not by those of patients on a gluten-free
diet. This peptide shares homology with the rotavirus major neutralizing protein VP-7 and with
the self-antigens tissue transglutaminase, human heat shock protein 60, desmoglein 1, and
Toll-like receptor 4. We show that antibodies against the peptide affinity-purified from the sera
of patients with active disease recognize the viral product and self-antigens in ELISA and
Western blot. These antibodies were able to induce increased epithelial cell permeability
evaluated by transepithelial flux of [3H] mannitol in the T84 human intestinal epithelial cell line.
Finally, the purified antibodies induced monocyte activation upon binding Toll-like receptor 4,
evaluated both by surface expression of activation markers and by production of pro-
inflammatory cytokines.
Conclusions
Our findings show that in active celiac disease, a subset of anti-transglutaminase IgA
antibodies recognize the viral protein VP-7, suggesting a possible involvement of rotavirus
infection in the pathogenesis of the disease, through a mechanism of molecular mimicry.
Moreover, such antibodies recognize self-antigens and are functionally active, able to increase
intestinal permeability and induce monocyte activation. We therefore provide evidence for the
involvement of innate immunity in the pathogenesis of celiac disease through a previously
unknown mechanism of engagement of Toll-like receptor 4.
The Editors’ Summary of this article follows the references.
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Introduction
Gluten enteropathy is a chronic systemic autoimmune
disorder [1,2] sustained by an inappropriate immune response
to dietary gluten [3], that may affect as many as 1%–3% of the
European and North American population [4]. Genetically
susceptible individuals develop autoimmune injury to the gut,
skin, joints, liver, brain, heart, uterus, and other organs. In
addition, celiac patients show an increased prevalence of other
autoimmune diseases. Celiac disease (CD) is considered a
model for autoimmune disorders because the crucial genetic
and environmental factors responsible for its pathogenesis
have been identified. It is well known that the interplay of four
components induces enteropathy: gluten/gliadin, gluten-spe-
cific T cells, the major histocompatibility complex locus HLA-
DQ, and the endogenous enzyme tissue transglutaminase (tTG)
[1]. tTG can deaminate glutamine to glutamic acid, producing
the negatively charged residues necessary for efficient binding
to DQ2 and for T cell activation. Genetic, molecular, and
functional studies have clarified the powerful Th1-dominated
pro-inflammatory response that characterises the small intes-
tine of patients with active CD. Moreover, patients with active
CD have immunoglobulin (Ig)A and IgG antibodies directed
against tTG [5]. The disease enters complete remission, and
anti-tTG antibodies are no longer detectable when gluten is
eliminated from the diet (gluten-free diet [GFD]) [6].
In addition to the activation of adaptive immune response,
recent evidence suggests that innate immunity might play a
role in the initial phases of CD [7]. Indeed, some gluten
peptides seem to be able to directly activate the innate
immune system [8]. Moreover, infectious agents are thought
to play a role in the pathogenesis of the disease [9,10].
A key feature of the early stages of CD is the presence of
increased intestinal epithelial cell permeability [1,10,11]. One
of the mechanisms involved is related to tight-junction
derangement [12]. However, alterations involving other types
of junctional adhesion may contribute to the increased
epithelial permeability.
Despite the huge progress in understanding the patho-
genesis of CD, facilitated by the knowledge of the genetic
background and of the well-defined environmental trigger
gluten/gliadin, there are still many unknowns, including the
presence of autoaggression in different tissues and the role
played by infections and by innate immunity.
In this study, we have identified an autoantigen peptide
that is recognized by serum Igs of patients with active disease
(on a gluten-containing diet [GCD]), but not by patients on
GFD. We show that antibodies against the peptide purified
from the sera of patients recognize the rotavirus major
neutralizing protein VP-7 [13] and self-antigens including
tTG [14], human heat shock protein 60 (HSP60) [15],
desmoglein 1 [16], and Toll-like receptor 4 (TLR4) [17,18].
The anti-peptide antibodies are pathogenetically relevant
because of their ability to alter the intestinal barrier integrity
and to activate monocytes through a previously unknown
mechanism of TLR4 stimulation.
Methods
Patients
Sixty patients affected by CD were enrolled in the study.
The first group included 22 patients with active disease, four
males and 18 females, aged 1–38 (mean¼ 16) y, at diagnosis of
biopsy confirmed CD and after a period of 5 mo to 9 y (mean
¼ 5.6 y) of GFD. A second group of 38 CD patients, 12 males
and 26 females, aged 1–56 (mean¼ 14) y, with active disease,
was also studied. All the patients had serum anti-gliadin and
anti-tTG antibodies. Antibodies against IgA, IgM, and IgG
were not detected in the sera of all the patients. The duodenal
histological damage at diagnosis ranged from grade 3a to 3c,
according to Marsh’s classification [19]. Patients on GFD were
negative for anti-tTG IgA antibodies. The majority of patients
suffered from gastrointestinal symptoms; the symptoms
present at diagnosis were: gastrointestinal (diarrhoea, abdo-
men distension, and cramps) in 39 out of 60 patients, and/or
extra-intestinal (iron deficiency anemia, dermatitis herpeti-
formis, spontaneous abortion, weight loss, astenia, growth
disturbances, and myopathy) in 25 out of 60 patients. One of
the patients with gastrointestinal symptoms had thrombocy-
topenia and no evidence of other autoimmune diseases, and
another one suffered from demyelinating CNS disease [20,21]:
in this latter patient, multiple sclerosis was excluded on the
basis of clinical follow-up, cerebrospinal liquid analysis, and
pattern of CNS demyelinization as seen at magnetic
resonance imaging. Some patients presented only mild or
minimal symptoms, and four patients were asymptomatic
(silent CD) with familial history of CD. The patients with CD
included in the study showed no evidence of co-existing
autoimmune diseases. Human leukocyte antigen (HLA)
haplotype was performed in 20 patients: 14 patients (70%)
were HLA DQ2 positive, four patients (20%) were HLA DQ8
positive, and two patients (10%) were HLA DQ2/DQ8
positive. Control sera were obtained from 60 healthy age-
and sex-matched individuals who had no evidence of auto-
immunity, were negative for anti-tTG and anti-gliadin anti-
bodies, and had no evidence of intestinal disease as assessed
by biopsy.
Sera from 90 patients with systemic sclerosis, from 50
patients with systemic lupus erythematosus, and from 40
patients with Crohn disease were also used as controls for
some experiments.
Cell Culture
T84 cells obtained from the American Type Culture
Collection (Manassas, Virginia, United States) were grown in
a 5% CO2 humidified incubator at 37 8C on 162-cm
2 flasks
(Corning Costar, Acton, Massachusetts, United States) with
media containing a 1:1 mixture of Ham’s F-12 nutrient
mixture and DMEM supplemented with 6% heat-inactivated
fetal bovine serum, 15 mM HEPES, 14.3 mM NaHCO3, and
antibiotics (penicillin and streptomycin)–antimycotics (pH
7.4). Cells were passaged weekly on reaching confluence. For
experiments, cells were plated onto collagen-coated perme-
able supports, where they were fed every 3 d and used from
days 7–14 (within fifth passage).
The 293T cells transfected with TLR4 or TLR9 as well as
their culture medium were purchased from Cayla-Invivogen
(Ruschlikon, Switzerland). Control untransfected 293T cells
were from Cayla-Invivogen. The human cell line K562 was
cultured under standard conditions (RPMI 10% FCS) [22].
Library
The FliTrx random dodecamer peptide library [23], which
displays peptides on the surface of Escherichia coli using the
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major bacterial flagellar protein (FliC) and thioredoxin (Lu),
was purchased from Invitrogen (Carlsbad, California, United
States) and screened with pooled Igs affinity purified from the
sera of the 22 patients with active disease on GCD according
to manufacturer’s instructions (FliTrx Panning Kit, Invitro-
gen). After five sequential rounds of biopanning experiments,
each preceded by a pre-panning step with pooled Igs
obtained from the same 22 patients on GFD to remove
bacteria that bound antibodies present in sera of patients
with inactive disease, the enriched library was grown and
single colonies picked, expanded, and induced with trypto-
phan to express the fusion peptides. Bacteria were then lysed
in sample buffer and tested in Western blot with the pooled
Ig fraction from patients on GCD to check for positive clones.
DNA was extracted from positive clones and sequenced with
an automated sequencing apparatus (Perkin Elmer, Norwalk,
Connecticut, United States).
A set of 15 peptides, out of the 27 peptides obtained from
the last biopanning round, was synthesized, excluding those
peptides that shared a high degree of homology with each
other (greater than 90%, which corresponds to ten out of 12
amino acid identities or conservative substitutions). The 15
synthetic peptides were used in an enzyme-linked immuno-
sorbent assay (ELISA) to test individual patients’ sera as well
as control Igs. At the end of the screening procedure, we
calculated the frequency of antibodies against the individual
peptides. In most cases, the reactivity was present in
approximately 5% of the patients; therefore, we did not
consider these sequences anymore. In one case, reactivity
against the synthetic peptide was present in approximately
65% of the patients’ sera (celiac peptide). Since no other
peptide was recognized by serum Igs at such frequency, we
focused our attention on this particular peptide. The celiac
peptide was already sequenced after the second biopanning
round and three times after the fifth round, indicating that
this reactivity is important since it was still present after five
steps of enrichment of the peptide library. Moreover, the fact
that we could obtain the same sequence from three
independently picked clones suggests that this peptide is
over-represented among the group of antibody-selected
peptide epitopes. Similar behaviour has been observed in
other screening procedures performed in our laboratory
using the sera of patients with autoimmune diseases [23–26].
Peptide Synthesis
All the synthetic peptides, including the celiac peptide, the
rotavirus VP-7 peptide (VIQVGGSNVLDI), the TLR4 peptide
(VLKMAGNSFQEN), the desmoglein 1-peptide (LSSLGGTA-
SIGH), the tTG peptide (RIRVGQSMNMGS) and the irrele-
vant control peptide (VTLPKDSDVELP), were manually
synthesized using the standard method of solid-phase peptide
synthesis, which follows the 9-fluorenylmethoxycarbonyl
(FMOC) strategy with minor modifications [27]. All the
synthesized compounds were purified by reverse-phase
high-performance liquid chromatography (RP-HPLC) and
the molecular weights finally confirmed by electrospray mass
spectrometry.
Affinity Purification of Total Human Serum
Immunoglobulins
Serum samples (1 ml per 3 ml of resin) were applied to T-
Gel Adsorbent Columns (Pierce Biotechnology, Rockford,
Illinois, United States). The columns were washed with
binding buffer. Bound Igs were eluted with eluting buffer
and dialyzed against PBS. All the reagents used for the
purification procedure were supplied by Pierce (T Gel
Purification Kit for total Ig purification). The purity of the
preparations was assessed by SDS-PAGE followed by silver
staining; sometimes, when albumin contamination was
present in the purified preparation, an additional step was
added using an Albumin Removal Kit (Pierce).The same
procedure was used to purify rabbit Igs from rabbit antisera.
Affinity Purification of Anti-Peptide Antibodies
The synthetic peptides (5 mg peptide per gram of dried
Sepharose powder) were coupled to Sepharose 4B (Pharma-
cia, Uppsala, Sweden) according to the manufacturer’s
instructions. Serum Igs (see previous section) diluted in PBS
were applied to the columns. The columns were washed with
PBS. Bound Ig were eluted with 0.1 M glycine (pH 2.5) and
dialyzed against PBS. The purity of the preparations was
assessed by SDS-PAGE followed by silver staining; sometimes,
when albumin contamination was present in the purified
preparation, an additional step was added using an Albumin
Removal Kit (Pierce). Antibody concentration matching was
performed using a densitometric analysis of a silver stain of
the purified material. When anti-peptide antibodies obtained
from different patients were pooled together and used in
functional experiments, each purified patient sample was
checked for the presence of the relevant peptide reactivity
individually before pooling.
Affinity Purification of Anti-Transglutaminase Antibodies
Commercially available recombinant human tTG (GST-
transglutaminase II fusion protein from E. coli, Labvision,
Fremont, California, United States) was coupled to Sepharose
4B (Pharmacia), 4 mg protein per gram of dried Sepharose
powder, according to manufacturer’s instructions. Serum Igs
diluted in PBS were applied to the columns. The columns
were washed with PBS. Bound Ig were eluted with 0.1 M
glycine (pH 2.5) and dialyzed against PBS. For this set of
experiments, two groups of serum Igs were used; the first one
included five patients’ sera that bound tTG but did not
recognize the celiac peptide in ELISA. Pooled serum Igs were
used to purify anti-tTG antibodies. The antibody preparation
obtained was checked in ELISA to assess its negativity on a
plate coated with the celiac peptide. The antibodies did not
bind the celiac peptide; however, they retained anti-tTG
activity assessed using the commercially available Eurospital
kit (Trieste, Italy). The antibody preparation contained
mostly IgA and approximately 10% of IgG specific for tTG.
The second group of sera contained antibodies specific for
tTG but failed to recognize both recombinant desmoglein 1
and the desmoglein-derived peptide (LSSLGGTASIGH).
Pooled sera from five such patients was used to purify anti-
tTG antibodies. The antibody preparation did not bind
desmoglein and the desmoglein 1 peptide; however, it still
recognized tTG. In order to remove any residual anti-celiac/
desmoglein peptide antibody activity, the purified anti-tTG
antibody preparations were then repeatedly applied either to
a celiac peptide-coupled Sepharose column or to a desmo-
glein peptide-coupled Sepharose column until the eluate
optical density (OD) reading was less than 0.0025.
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ELISA
The direct and competitive ELISA for antibody binding to
the synthetic peptides have already been described elsewhere
[23]. Briefly, the synthetic peptides were used at a concen-
tration of 20 lg/ml in PBS to coat polystyrene plates (Nunc,
Roskilde, Denmark). Plates were then blocked for 1 h with
PBS 3% BSA. Serum samples were diluted in diluting buffer
(PBS 1% BSA 0.05% Tween) and incubated on the plates for
3 h at room temperature. Plates were then washed twice with
PBS 1% Tween and twice with PBS. Bound antibodies were
detected by an alkaline phosphatase-conjugated anti-human
IgA antiserum (1:1,000 in diluting buffer) (Sigma, St. Louis,
Missouri, United States) or with an alkaline phosphatase-
conjugated anti-human IgG antiserum (1:2,000 in diluting
buffer) (Sigma). In some experiments, an alkaline phospha-
tase-conjugated anti-rabbit IgG antiserum (1:2,000 in diluting
buffer) (Sigma) was also used. The secondary reagents were
incubated overnight at 4 8C; plates were then washed twice
with PBS/Tween and twice with PBS. The alkaline phospha-
tase substrate (Sigma) diluted in bicarbonate buffer was then
added to the wells and the plates read after 30 min or 1 h at a
spectrophotometer set at 450 nm. For the competitive assay,
the amount of antibody (or serum dilution) that gave 50% of
the maximum binding to the antigen on the solid phase was
pre-incubated for 1 h at 37 8C with different amounts of
competitors (20, 10, 5, 2.5, 1.25, 0.6 lg/ml) or buffer (diluting
buffer as the one used in the direct ELISA) and then
transferred to the antigen-coated plates. The assay was then
carried on as the direct binding assay. For the competitive
ELISAs presented in this paper in particular, the following
experimental conditions were used. (1) Competitive ELISA
using tTG-coated plates. Plates coated with human recombi-
nant tTG were purchased from Eurospital. Serum samples in
diluting buffer (serum dilution ranged from 1:400 to 1:1,600
corresponding to 50% maximal binding to solid-phase tTG)
were pre-incubated with increasing concentration of com-
petitors (synthetic peptides or recombinant human tTG: 20,
10, 5, 2.5, 1.25, 0.6 lg/ml) for 1 h at 37 8C. The mixture was
then transferred to the tTG-coated plate. The remainder of
the assay was performed as the direct binding assay. Results
are expressed as:
% inhibition OD reading in the presence of competitor x 100
OD reading of the same serum dilution in the absence of competitor
:
(2) Competitive ELISA with desmoglein 1–coated plates.
Desmoglein 1–coated plates were purchased from MBL
(Woburn, Massachusetts, United States). Serum samples in
diluting buffer (serum dilution ranged from 1:400 to 1:800
corresponding to 50% maximal binding to solid-phase
desmoglein 1 were pre-incubated with increasing concen-
trations of competitors (synthetic peptides and recombinant
human tTG: 20, 10, 5, 2.5, 1.25, 0.6 lg/ml) for 1 h at 37 8C. The
mixture was then transferred to the desmoglein-coated plate.
In this particular assay, we used the desmoglein 1 peptide as
liquid-phase competitor, since the only liquid-phase recombi-
nant desmoglein 1 available is an Fc chimera.
In the ELISA for the detection of serum antibodies
directed against the peptides, 60 sera diluted 1:200 from
normal age- and sex-matched participants were used as the
control group. OD values higher than the mean plus three
standard deviations (SD) of each serum dilution of the
control group were considered positive. Cut-off threshold
OD values were 0.200 for anti-celiac peptide IgA antibodies,
0.250 for IgG anti-celiac peptide antibodies, 0.180 for IgA
anti-VP-7 peptide, 0.220 for IgG antibodies against VP-7
peptide, 0.210 for IgA antibodies against the desmoglein 1
peptide, 0.260 for IgG antibodies against desmoglein 1
peptide, 0.190 for IgA antibodies against the TLR4 peptide,
and 0.220 for IgG antibodies against the TLR4 peptide.
Commercially available kits were used to detect anti-tTG
antibodies (recombinant human tTG) (Eurospital), (cut-off
threshold value for IgA anti-tTG ¼ 7 units/ml), anti-HSP60
antibodies (Stressgen, Victoria, British Columbia, Canada)
(cut-off threshold OD value for IgA anti-HSP60¼ 0.150), and
anti-Salmonella antibodies (Bio Quant, San Diego, California,
United States) (cut-off threshold OD value for IgG anti-
Salmonella typhi ¼ 0.120, and for IgA anti-Salmonella ¼ 0.150).
Anti-Saccharomyces cerevisiae antibodies (ASCA) have been
performed using a commercially available kit (Alpco Diag-
nostics, Windham, New Hampshire, United States). (Cut-off
threshold value for ASCA IgG and IgA is 10 U/ml). Anti-
rotavirus antibodies were detected using a commercially
available viral extract (Virion, Ruschlikon, Switzerland). The
extract was used at a concentration of 25 lg/ml in PBS to coat
polystyrene plates (Nunc, Roskilde, Denmark). Plates were
then blocked for 1 h with PBS 3% BSA. Serum samples were
diluted in diluting buffer (PBS 1% BSA 0.05% Tween) and
incubated on the plates for 3 h at room temperature. Plates
were then washed twice with PBS 1% Tween and twice with
PBS. Bound antibodies were detected by an alkaline
phosphatase-conjugated monoclonal anti-human IgG anti-
body (Zymed). Positive and negative control sera were
purchased from Virion. The OD readings after 30 min of
colour development were 0.130 for the negative control
serum and 0.650 for the positive control. The meanþ 3 SD of
the control group was an OD of 0.200. Therefore, we
considered positive only the sera whose OD readings were
higher than 0.200. By using this criteria, some sera of patients
with CD were considered negative. However, all of these sera
had an OD reading greater than the one observed with the
negative control serum, between 0.130 and 0.200; therefore,
in theory they are all above the levels of the reference
negative serum sample and can be considered borderline.
Anti-rotavirus IgA antibodies were detected similarly, the
only difference being the secondary antibody used (alkaline
phosphatase-conjugated anti-human IgA antiserum, 1:1,000
in diluting buffer, purchased from Sigma). The OD readings
after 30 min of colour development were 0.190 for the
negative control serum and 0.550 for the positive control.
The mean þ 3 SD of the control group was an OD of 0.260.
Therefore, we considered positive only the sera whose OD
readings were higher than 0.260.
DELFIA
The dissociation-enhanced lanthanide fluorescent immu-
noassay (DELFIA) assay is a time-resolved fluorescence
method that can be used to study antibody binding to solid-
phase proteins or peptides. The celiac peptide was used at a
concentration of 20 lg/ml in PBS to coat DELFIA plates
(Perkin Elmer). Plates were then blocked for 1 h with a
blocking reagent (Perkin Elmer). Serum samples were diluted
in diluting buffer (Perkin Elmer) and incubated on the plates
overnight at 4 8C. Plates were then washed ten times with
washing buffer (Perkin Elmer). Bound antibodies were
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detected with a europium-labelled anti-human IgA antiserum
(1:500 in diluting buffer) (Perkin Elmer) or with a europium-
labelled anti-human IgG antiserum (1:500 in diluting buffer)
(Perkin Elmer). Plates were read on a Victor 3 instrument
(Perkin Elmer) and the data analyzed with software supplied
with the DELFIA instrument. For the detection of anti-
rotavirus antibodies, the viral extract was used at a concen-
tration of 25 lg/ml in PBS to coat DELFIA plates, and the
remainder of the assay was performed as already described. In
the DELFIA for the detection of serum antibodies directed
against either the celiac peptide or the viral extract, 60 sera
diluted 1:200 from normal age- and sex-matched participants
were used as the control group. OD values higher than the
mean þ 3 SD of each serum dilution of the control group
were considered positive.
Detection of Anti-Endomysial Antibodies by Indirect
Fluorescent Assay
Anti-endomysial antibodies were determined using a
commercially available kit (Diamedix, Miami, Florida, United
States) following manufacturer’s instructions. Briefly, the
antigen slides of primate distal esophagus (endomysial
section) were incubated with 50 ll (1 lg/ll) of either purified
anti-celiac peptide antibodies cross-reacting with the VP-7
rotavirus peptide or purified anti-VP-7 antibodies for 30 min.
After washing for 20 min in PBS, 50 ll of the secondary FITC
conjugated anti-human IgA or IgG antibodies were applied to
the antigen wells for 30 min.
Rabbit Antiserum Production
Polyclonal antibodies were generated in New Zealand
White rabbits by using standard techniques. Immunizations
were performed with a peptide corresponding to VP-7 amino
acid residues 260 to 271 (VIQVGGSNVLDI) coupled to the
carrier protein keyhole limpet hemocyanin (KLH) (Sigma)
and with a peptide corresponding to myotubularin-related
protein 2 (MTMR2) amino acid residues 135 to 146
(VEKIGGASSRGE) coupled to KLH. The antisera were tested
by ELISA on peptide-coated plates, and the anti-peptide
fraction was purified by affinity chromatography on peptide-
Sepharose columns. The anti-VP-7 peptide antibodies bound
the VP-7 peptide, the TLR4 peptide, and the celiac peptide;
moreover, they specifically recognized recombinant tTG and
desmoglein 1.
Western Blot
A rotavirus extract (Virion) was used to detect the VP-7
protein in immunoblot. The extract was enriched for the VP-
7 protein by affinity chromatography using a VP-7 peptide
Sepharose column. The presence of contaminant tTG in the
commercial rotavirus extract was excluded by using the
monoclonal anti-tTG purchased from Labvision (clone CUB
7402). A cell lysate of 293T cells transfected with the TLR4
gene (Cayla-Invivogen) was used to detect TLR4 in Western
blot using a TLR4-specific monoclonal antibody (clone
76B357.1, IgG2a, Imgenex, San Diego, California, United
States). Blots were probed with primary antibodies followed
by either peroxidase-linked anti-human Igs antibodies, anti-
human IgA antibodies, anti-rabbit IgG antibodies, or anti-
mouse IgG antibodies (all purchased from Sigma). Binding to
desmoglein 1 was assessed using the human recombinant
desmoglein 1 molecule (Fc chimera) (R&D Systems, Minne-
apolis, Minnesota, United States) in Western blot. Blots were
incubated with biotin-labelled, affinity-purified anti-peptide
antibodies followed by peroxidase-labelled avidin, or with
patients’ sera followed by peroxidase-labelled anti-human
IgA antibodies.
Stimulation of Monocytes
Human monocytes were isolated from normal donors and
incubated overnight at a density of 1 3 106 cells/ml in RPMI
10% FCS in 24-well plates in the presence of the antibody
preparations (20 lg/ml) or lipopolysaccharide (LPS) (1 lg/ml)
(Sigma). The medium used and all the antibody preparations
were treated with Detoxi-gel endotoxin-removing columns
(Pierce). Presence of LPS contaminants in the antibody
preparation and buffers as well as in the culture medium
was assessed using the HEK-Blue LPS Detection Kit (Inviv-
ogen); all the antibody preparation and buffers used
throughout the study were devoided of LPS contaminants.
Monocytes were then used for fluorescence-activated cell
sorting (FACS) analysis.
Activation of TLR4 by Antibodies
TLR4 signalling leads to translocation of nuclear factor–
kappaB (NF-jB). To monitor the induction of TLR4 signal-
ling in response to ligand stimulation, we have used the
pNifty reporter plasmid (Invivogen), expressing the secreted
embryonic alkaline phosphatase gene (SEAP) under the
control of a NF-jB-inducible ELAM 1 composite promoter
[28]. This composite ELAM 1 promoter is truly NF-jB specific
and drives the expression of a reporter gene (SEAP) that is
induced in the presence of NF-jB and repressed in the
absence of the transcription factor. Engineered 293T cells
stably transfected with TLR4 and the co-receptors MD2 and
CD14 (Invivogen) were co-transfected with the pNifty
plasmids and stable transfectants selected in the presence of
phleomycin D1 (Zeocin, Invivogen), as selection agent; 293T
cells transfected with TLR9 (Invivogen) and co-transfected
with the pNifty plasmid were used as control. Stable trans-
fectants were grown in DMEM high glucose supplemented
with 10% FCS, penicillin-streptomycin, and Normocin (In-
vivogen). Cells were grown to 60%–80% confluence in growth
medium and then harvested and re-suspended in HEK-Blue
Detection medium (Invivogen). This medium is specifically
designed for detection of NF-jB activation since it turns blue
in the presence of phosphatase activity. The product of the
reaction is cytotoxic and results in the death of the cells. 2.53
104 cells/well (in 200 ll of medium) were plated in 96-well
plates in the presence of the appropriate stimuli (purified
endotoxin-free antibody preparation, final concentration 4,
2, 1, and 0.5 lg/ml). Positive control for TLR4 was LPS
(Invivogen), while the stimulatory oligonucleotide with
human-specific type B CpGs (oligodeoxynucleotide 2006
sequence 59- tcg tcg ttt tgt cgt ttt gtc gtt 39) (Invivogen)
was used for TLR9 cells. Cells were incubated for 24 h at 37 8C
in 5% CO2 and the blue colour assessed by a spectropho-
tometer set at 620 nm. All the antibody preparations used in
this set of experiments were devoided of LPS contaminants
(see previous section). Results are expressed as percentage of
positive control, where the positive control is the OD value
obtained upon stimulation of TLR4-transfected cells with 100
ng/ml LPS (maximal concentration used).
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FACS Analysis
Cells were incubated with R-phycoerythrin directly con-
jugated anti-CD1, -CD83, and -CD86 antibodies for 30 min on
ice. For anti-CD40, antibody binding was revealed using R-
phycoerythrin-conjugated secondary antibodies. Samples
were run on a FACScan flow cytometer (Becton Dickinson,
Mountain View, California, United States). All the antibodies
used were purchased from Immunotech (Marseille, France).
Cytokines Measurement
The levels of interleukin-6 (IL-6), IL-12, and tumour
necrosis factor alpha (TNF-alpha) released in the supernatant
of cultured monocytes after activation with either LPS or
affinity purified anti-celiac peptide antibodies or other
stimuli, were determined using commercially available ELISA
kits (Biosource International, Camarillo, California, United
States) following manufacturer’s instructions. The anti-TLR4
monoclonal antibody clone HTA125, isotype IgG2b (Imge-
nex), was used for inhibition experiments.
[3H] Mannitol Flux
Confluent T84 monolayers grown on 4.7 cm2 transwell
inserts were incubated in HEPES-phosphate-buffered Ringer
solution (HPBR, containing 135 mM NaCl, 5 mM KCl, 3.33
mM NaHPO4, 1 mM CaCl2, 1 mM MgCl2, 10 mM glucose, and
5 mM HEPES [pH 7.4]) for 30 min, followed by treatment with
basolaterally applied Igs (20 lg/ml) in the presence of [3H]
mannitol (5 lCi/ml) in the basolateral compartment. Apical
solution was sampled every 30 min (to detect the presence of
[3H] mannitol) and exchanged with fresh HPBR buffer
solution for a total of 4 h. The collected apical samples were
placed in vials containing scintillation fluid and analyzed for
the presence of [3H] mannitol by scintillation counter.
Statistical Analysis
Frequency of anti-infectious agents antibodies in patients
and controls was analyzed by using the chi-square test.
Difference in mannitol concentration in the supernatants
of treated and untreated cells at different given times was
performed by using the non-parametric Mann-Whitney ‘‘U’’
test.




We have screened a dodecamer random peptide library
[23] with pooled Igs derived from a panel of 22 patients with
active CD after a pre-screening with Igs obtained by the same
22 patients on GFD and negative for the presence of anti-tTG
IgA antibodies. By this approach, we aimed to identify only
those peptides possibly relevant to the pathogenesis of the
disease.
We identified a peptide (celiac peptide: VVKGGSSSLGW)
that was specifically recognized by serum IgA of 15 out of 22
(68%) individual patients with active disease on GCD and by
serum IgA of only four of the same 22 patients on GFD, by
both direct and competitive ELISA (Figure 1A). Such
reactivity was not detected by the individual sera of 60
healthy individuals. In another group of 38 patients with
active disease, whose sera were not used for the screening of
the library, 25 individuals (65.7%) had serum IgA against the
celiac peptide. The frequency of IgG antibodies against the
celiac peptide is 68.3% (41 out of 60 patients). IgA reactivity
towards the celiac peptide was not detected in 90 out of 90
patients with systemic sclerosis, and 50 out of 50 patients with
systemic lupus erythematosus. We have also tested a panel of
sera obtained from patients with small bowel disease: IgA
reactivity against the celiac peptide was not detected in 40
out of 40 patients with Crohn disease. IgG antibodies against
the celiac peptide were detected in two out of 90 patients
with systemic sclerosis, in one out of 50 patients with systemic
lupus erythematosus, and in three out of 40 patients with
Crohn disease.
These data indicate that this celiac peptide sequence
contains an epitope recognized at high frequency by the sera
of patients with active disease, but not by patients on GFD.
Detection of Anti-Celiac Peptide Antibodies by DELFIA
DELFIA is a powerful tool used to analyze antibody binding
to a solid-phase antigen; this technique is far more sensitive
than ELISA and allows better identification of low–moderate
antigen–antibody interactions. We therefore used this meth-
od to test the panel of the 22 celiac patients’ sera for their
ability to recognize the celiac peptide. Using this approach,
20 out of 22 patients’ sera had detectable IgA antibodies
against the celiac peptide. Out of the five patients’ sera that
were negative in ELISA, four serum samples showed a
moderate positivity towards the celiac peptide, and one
patient was only slightly positive, still above threshold. IgA
antibodies against the celiac peptide were still detectable in
four out of 22 patients with CD in GFD. This reactivity was
absent in the 60 controls’ sera.
These results indicate that the use of DELFIA in the
screening procedure is more sensitive than the use of ELISA
and can help to identify sera with moderate antibody binding
activity towards a given epitope.
Anti-Celiac Peptide Antibodies Recognize the Rotavirus-
Derived Protein VP-7
Since in CD a transient infection may facilitate the uptake
of gluten peptides into the small intestinal mucosa [11], we
decided to compare the celiac peptide sequence with known
microbial sequences in a protein data bank (Swiss-Prot
database) using the BLASTP via the NCBI BLAST network
service, and found that the peptide sequence shared a high
degree of homology with different proteins, including
rotavirus serotype I major neutralizing protein VP-7 [13], S.
typhi D-cysteine desulfhydrase, and S. cerevisiae HSP60 (Figure
1B). Two criteria were used in selecting such microbial
proteins: the first is the extent of homology calculated by
measuring the length of the homologous stretch and the
number of matched amino acids (both identities and
conservative substitutions were considered); the second one
is based on the nature of the infectious agents. We privileged
those agents that can be potentially involved in human
pathology. Since these infectious agents are all correlated
with intestinal damage, we evaluated the prevalence of serum
IgG antibodies against such agents in 60 patients with active
CD. We found that only four patients had antibodies directed
against S. cerevisiae (6.6 %), and 25 patients had antibodies
against S. typhi (41,6%), whereas the large majority of patients
(52 out of 60: 86.6%) had antibodies against rotavirus in
ELISA, and all of them had antibodies against rotavirus in
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Western blot (Figure 1C). The use of DELFIA partially
corrected the discrepancies observed between the ELISA
and the Western blot in the detection of IgG anti-rotavirus
antibodies. By using DELFIA, 58 out of 60 (96.6%) patients’
sera showed the presence of IgG anti-rotavirus antibodies,
while there was no significant modification in the number of
normal controls positive for the presence of IgG anti-
rotavirus (18 out of 60 controls).
IgA antibodies against Saccharomyces were not detected in
patients’ sera, anti-Salmonella antibodies were present in eight
out of 60 patients (13.3%), and IgA antibodies against
rotavirus were present in 41 out of 60 patients (68.3%). The
frequency of IgG antibody reactivity against S. typhi and
Saccharomyces did not differ among patients and control
participants. On the contrary, the frequency of antibodies
against rotavirus was significantly higher in patients than in
control participants (p , 0.0001). Moreover, we have tested
the patients’ sera for their ability to recognize the VP-7
peptide in ELISA; 55 out of 60 patients’ sera (91%) had IgG
antibodies against the VP-7 peptide, while IgA antibodies
against the peptide were present in 45 out of 60 patients’ sera
(75%). These data indicate that the VP-7 peptide contains a
crucial epitope of the anti-rotavirus antibody response in
individuals affected by CD.
We therefore decided to focus our attention on the viral
protein for the following experiments. We next isolated the
antibody component against the celiac peptide from individ-
ual sera of ten patients on GCD by affinity chromatography
using a peptide Sepharose column. The affinity-purified
antibodies specifically recognized the protein VP-7 (Figure
1D) that represents a major neutralization protein of
rotaviruses. IgA antibodies against the viral protein VP-7
Figure 1. Celiac Peptide Is Recognized by Sera of Patients with Active Disease and Shares Homology with Microbial Antigens
(A) The celiac peptide is recognized by serum IgA immunoglobulins of patients on GCD, but not by patients on GFD. Results are expressed as
absorbance at 405 nm.
(B) Sequence homology between the celiac peptide and infectious agents. The peptide sequence was compared with known microbial protein
sequences using the BLASTP via the NCBI BLAST network service (: indicates identity and * indicates conservative substitutions).
(C) Frequency of IgG antibodies directed against infectious agents in patients with active CD and in normal healthy controls.
(D) Sera of patients with active CD contain IgA antibodies directed against the rotavirus major neutralizing protein VP-7. A rotavirus extract was probed
with rabbit antiserum raised against a peptide (VIQVGGSNVLDI) of the VP-7 protein (Lane 1), with affinity-purified anti-celiac peptide antibodies (Lane
2), with antibodies affinity-purified against an irrelevant control peptide (Lane 3), with sera from adult patients with active disease (Lanes 4 and 5), with
sera from the same patients on GFD (Lanes 7 and 8), and serum from a 1-y-old child with active CD (Lane 6) and on GFD (Lane 9). A peroxidase-labelled
polyvalent anti-human Igs antibody (Lanes 2 and 3) and an anti-human IgA antibody (Lanes 4–9) were used for detection.
DOI: 10.1371/journal.pmed.0030358.g001
PLoS Medicine | www.plosmedicine.org September 2006 | Volume 3 | Issue 9 | e3581643
Innate Immunity in Celiac Disease
were present in 17 out of 22 adult patients with active disease
and disappear in all the same patients on GFD. Three
children within 1 y of age maintained the presence of anti-
VP-7 IgA also on GFD (representative examples are shown in
Figure 1D). On the contrary, IgG antibodies against the viral
protein VP-7 are present in all the patients with inactive
disease (unpublished data).
These results indicate that IgA antibodies directed against
the celiac peptide recognize the viral protein only in patients
with active disease, suggesting a possible etiological link
between viral infection and CD.
Anti-Celiac Peptide Antibodies Recognize Self-Antigens
As CD is characterized by autoimmune injury in different
tissues [2,4], we next compared the celiac peptide sequence
with human proteins in a protein data bank (Swiss-Prot
database of known human sequences) using the BLASTP via
the NCBI BLAST network service, and found that the peptide
shared a high degree of homology with different self-antigens,
including tTG, HSP60, MTMR2 [29], and TLR4 (Figure 2A).
Affinity-purified antibodies against the celiac peptide
bound the recombinant human tTG and HSP60 (Figure 2B).
Moreover, serum IgA antibodies directed against tTG and
HSP60 detected in patients with active disease disappear
following GFD (Figure 2C and 2D), as already observed for
anti-celiac peptide-specific IgA antibodies. The binding of
patients’ sera Igs to solid-phase tTG and HSP60 was inhibited
by pre-incubation of sera with either the tTG peptide, the
celiac peptide, or the VP-7 peptide (representative examples
are shown in Figure 2E and 2F). IgA antibodies against
MTMR2 were present in 14 out of 22 patients with active
disease, and such reactivity was lost in 13 out of 14 patients in
GFD (Figure 3A). One patient in GFD retained a low
reactivity against MTMR2. These findings indicate that the
tTG sequence (amino acid 476–487) homologous to the celiac
peptide is a key epitope in anti-tTG autoantibody recognition
[30]. Indeed, the importance of this area of the molecule in
autoantibody recognition has been already described, since
deletion of residues 473–496 completely abolished autoanti-
body reactivity of all the tested celiac sera [31].
The celiac peptide also shares homology with the extrac-
ellular region of TLR4, an essential receptor for LPS
recognition. Affinity-purified antibodies against the celiac
peptide recognized TLR4 both in 293T cells transfected with
TLR4 and in human monocytes (Figure 3B).
Altogether, these results indicate that purified anti-celiac
peptide antibodies bind the autoantigen tTG and other self-
antigens and that the reactivity of serum IgA to these self-
proteins is present only in patients with active disease and
disappears on GFD.
Anti-Celiac and Anti-VP-7 Peptide Antibodies Bind
Endomysium
Since the anti-tTG antibodies able to bind endomysial
structures may appear early during the onset of the disease,
even before the villous atrophy develops, we have tested the
ability of purified anti-celiac peptide antibodies and of anti-
VP-7 peptide antibodies to bind endomysium. Purified anti-
VP-7 antibodies are able to recognize the celiac peptide, tTG,
desmoglein, and TLR4; therefore, their possible endomysial
binding property would further support the relationship
between rotavirus infection and CD. Figure 4A–4F shows that
anti-VP-7 peptide antibodies indeed recognize endomysium
as well as anti-celiac peptide antibodies.
Anti-Celiac Peptide Antibodies Induce Monocyte
Activation
Since activation of the innate immune system has been
suggested to have a significant role in the induction and
maintenance of many CD manifestations [8], we next decided
to evaluate whether the interaction between affinity-purified
anti-celiac peptide antibodies and TLR4 expressed on
monocytes could have any functional relevance. Monocytes
were therefore incubated overnight either with affinity-
purified anti-celiac peptide antibodies, or with antibodies
purified against an irrelevant control peptide, or with LPS.
The monocyte activation markers considered were evaluated
by FACS analysis: in particular, CD83 and CD40 were
expressed with a similar fluorescence intensity and by a
similar percentage of monocytes after incubation with
affinity-purified anti-celiac peptide antibodies, with pooled
Igs from patients with active disease and with LPS. These
findings were not obtained with pooled Igs from the same
patients with inactive disease (Figure 5). These results were
confirmed by the measurement of IL-6, IL-12, and TNF-alpha
secreted in the medium (Figure 6A–6C). Cytokine production
was inhibited by pre-incubation of monocytes with a blocking
anti-TLR4 monoclonal antibody, confirming that monocyte
activation was indeed mediated by the anti-peptide anti-
bodies through TLR4 engagement.
These data indicate that in CD, autoantibodies are able to
bind TLR4 and activate monocytes.
Anti-Celiac Peptide Antibodies Activate TLR4 in Cells
Stably Transfected with the TLR4 Gene
293T cells stably transfected with the genes coding for TLR4
and the co-receptors MD2 and CD14 (Invivogen) as well as
Figure 2. Antibodies against the Celiac Peptide Bind the Self-Antigens tTG and HSP60
(A) Sequence homology between the celiac peptide and self-proteins (colons indicate identity and asterisks indicate conservative substitutions).
(B) Direct binding of affinity-purified antibodies against the celiac peptide to recombinant tTG (¤) and to recombinant HSP60 (n). Binding of affinity-
purified antibodies against the control peptide to tTG (m) and to HSP60 (X). Antibodies against the celiac peptide were purified from ten individual
patients with CD; representative example of purified antibodies from one patient is shown. The antibodies obtained from the other nine patients
behaved similarly. Data represent absorbance at 405 nm; antibody concentration (horizontal axis), lg/ml.
(C) Serum IgA Igs from the 22 patients on GCD, but not from the same patients on GFD, recognize tTG. Data represent U/ml.
(D) Serum IgA Igs from the 22 patients on GCD, but not from the same patients on GFD, recognize HSP60. Results are expressed as absorbance at 405
nm.
(E) Inhibition of binding of anti-celiac peptide antibodies to solid-phase tTG by liquid-phase tTG peptide (blue line), by celiac peptide (orange line), and
VP-7 peptide (red line), but not by an irrelevant control peptide (green line).
(F) Inhibition of binding of anti-celiac peptide antibodies to solid-phase HSP60 by liquid-phase tTG peptide (blue line), by celiac peptide (yellow line),
and VP-7 peptide (red line), but not by an irrelevant control peptide (green line). The y-axis represents percentage of inhibition, and the x-axis indicates
inhibitor concentration (lg/ml).
DOI: 10.1371/journal.pmed.0030358.g002
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293T cells expressing the TLR9 gene were co-transfected with
the pNifty plasmid (Invivogen) and stable transfectants
selected with Zeocin. In order to study the ability of antibodies
to engage TLRs and activate NF-jB, cells were stimulated in
the presence of either specific ligands (LPS for TLR4-positive
cells and oligodeoxynucleotides for TLR9-positive cells) or
purified-endotoxin-free antibodies. Figure 7 shows the results
obtained. Affinity-purified anti-celiac peptide antibodies were
able to activate TLR4 in 293T cells transfected with the TLR4
gene. Similar behaviour was observed for affinity-purified
antibodies directed against the VP-7 peptide. On the contrary
antibodies affinity purified against the irrelevant peptide and
antibodies affinity purified against tTG, which did not
recognize the celiac peptide, had no effects on TLR4-trans-
fected cells. None of the antibody preparations tested had any
effect on TLR9-transfected cells (unpublished data). These
data show that affinity-purified antibodies against celiac
peptide and against the VP-7 peptide have the ability to
activate NF-jB upon engagement of TLR4.
Anti-Celiac Peptide Antibodies Recognize Desmoglein 1
Increased intestinal epithelial cell permeability is a key
feature of the early stages of CD, and since the celiac peptide
shows sequence homology with cell junction proteins includ-
ing desmoglein 1 [16], a major component of intercellular
desmosome junctions (Figure 8A), we sought to determine
whether affinity-purified antibodies against the celiac peptide
were able to recognize desmoglein 1. Indeed, the antibodies
bound recombinant desmoglein 1 (Figure 8B), and IgA
antibodies directed against desmoglein 1 were detected in
18 out of 22 patients’ sera. Such reactivity was abolished in all
18 patients’ serum samples in GFD. Representative examples
of this behaviour are shown in Figure 8B.
In order to investigate whether the anti-celiac peptide
antibodies that recognize desmoglein 1 cross-react with tTG
and TLR4, a competitive ELISA was performed. The binding
of affinity-purified anti-celiac peptide antibodies to solid-
phase desmoglein 1 was inhibited by desmoglein 1, tTG, celiac
peptide, VP-7 peptide, and TLR4 peptide, but not by the
irrelevant control peptide (Figure 8C). These results show
that celiac patients’ sera contain an antibody population able
Figure 3. Antibodies against the Celiac Peptide Bind the Self-Antigens
MPMR2 and TLR4
(A) Sera of patients with active CD contain IgA antibodies directed
against MPMR2; such reactivity is not present in patients on GFD. A K562
cell lysate was probed with rabbit antiserum raised against a peptide
(VEKIGGASSRGE) of the MPMR2 (Lane 1), with antibodies affinity-purified
against the celiac peptide (lane 2), with antibodies affinity-purified
against an irrelevant control peptide (Lane 3), with sera from patients
with active disease on GCD (Lanes 4, 6, and 8), and with sera from the
same patients on GFD (Lanes 5, 7, and 9). A peroxidase-labelled
polyvalent anti-human Igs antibody (Lanes 2 and 3) and an anti-human
IgA antibody (Lanes 4–9) were used for detection.
(B) Cell lysate from untransfected 293T cells was probed with the
monoclonal antibody against TLR4 (Lane 1). Cell lysate from 293T cells
transfected with the human TLR4 gene was probed with a monoclonal
antibody directed against TLR4 (Lane 2), and with antibodies affinity-
purified against the celiac peptide (Lane 3). Cell lysate from 293T cells
transfected with the TLR4 gene was probed with biotin-labelled anti-
TLR4 monoclonal antibody (Lane 4). Cell lysate from 293T cells
transfected with the TLR4 gene was probed first with affinity-purified
anti-peptide antibodies, followed by an incubation with biotin-labelled
anti-TLR4 monoclonal antibody (Lane 5). Cell lysate from human
plasmocytoid dendritic cells was probed with the monoclonal antibody
against TLR4 (Lane 6). Cell lysate from human monocytes was probed
with the monoclonal antibody against TLR4 (Lane 7) and with affinity-
purified anti-peptide antibodies (Lane 8).
(C) Inhibition of binding of anti-celiac peptide antibodies to solid-phase
TLR4 peptide by liquid-phase TLR4 peptide (blue line), by celiac peptide
(red line), and VP-7 peptide (red line), but not by an irrelevant control
peptide (green line). The y-axis represents percentage of inhibition, and
the x-axis indicates inhibitor concentration (lg/ml).
DOI: 10.1371/journal.pmed.0030358.g003
Figure 4. Purified Antibodies Directed against Celiac and VP-7 Peptides
Bind Endomysial Structures
Pooled affinity-purified antibodies against celiac (A and D) and VP-7 (B
and E) peptides from ten patients bind endomysium. Purified antibodies
against the irrelevant control peptide from five patients (C and F).
(A–C) Slides stained with FITC conjugated anti-human IgA antibodies.
(D–F) Slides stained with FITC conjugated anti-human IgG antibodies.
DOI: 10.1371/journal.pmed.0030358.g004
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Figure 5. Antibodies against the Celiac Peptide Activate Monocytes
FACS analysis of monocytes following incubation with medium alone (A), with antibodies affinity-purified against the control peptide from five patients
with CD (B), with LPS (C), antibodies affinity-purified against the celiac peptide from ten patients with active CD (D), pooled Igs from the 22 patients on
GCD (E), and pooled Igs from the same patients on GFD (F). Percentage of positive cells¼CD83: 9.4% (a), 4.6% (b), 45 % (c), 40% (d), 48% (e), 11.9% (f);
CD40: 62.3% (a), 62.3% (b), 89% (c), 88.2% (d), 91.4% (e), 61% (f). Representative example of five independently performed experiments that generated
the same FACS profiles.
x-Axis: FL2-H, fluorescence intensity; y-axis: cell counts.
DOI: 10.1371/journal.pmed.0030358.g005
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to recognize desmoglein 1, tTG, TLR4, and rotavirus VP-7
protein.
Anti-Celiac Peptide Antibodies Induce Increased Epithelial
Cell Permeability
We then evaluated whether affinity-purified anti-celiac
peptide antibodies were able to alter intestinal epithelial cell
permeability. Affinity-purified antibodies against the celiac
peptide induced a time-dependent increase in the trans-
epithelial flux of [3H] mannitol from the basolateral to the
apical compartment (Figure 9A) in T84 human intestinal
epithelial cell line [32], used to study the epithelial barrier
function. The divergence of flux rate between monolayers
treated with antibodies against the celiac peptide and against
an irrelevant peptide reached significance after 3 h. This
increased permeability was also observed with affinity-
purified antibodies directed against the tTG peptide, against
desmoglein 1 peptide, against the TLR4 peptide, and against
Figure 6. Pro-Inflammatory Cytokines Produced by Activated Monocytes
Levels of IL-6 (A), IL-12 (B), and TNF-alpha (C) released in the supernatant
by monocytes incubated with medium alone (Line 1), with antibodies
directed against an irrelevant peptide (Line 2), with LPS (Line 3), with
pooled Igs isolated from the 22 patients with active CD (Line 4), with
pooled Igs isolated from the same patients on GFD (Line 5), with purified
anti-celiac peptide antibodies obtained from ten patients (line 6), with
purified anti-celiac peptide antibodies in the presence of an irrelevant
mouse IgG2b antibody (20 lg/ml) (Line 7), and with purified anti-celiac
peptide antibodies in the presence of the neutralizing mouse mono-
clonal antibody anti-TLR4, clone HTA 125 (20 lg/ml) (Line 8). The y-axis
represents the cytokine concentration expressed as pg/ml. Data
represent the mean 6SD of three independently performed experi-
ments.
DOI: 10.1371/journal.pmed.0030358.g006
Figure 7. Anti-Celiac Peptide Antibodies Activate TLR4 in Cells Trans-
fected with the TLR4 Gene
Activation of NF-jB upon engagement of TLR4.
(A) Stimulation of 293T cells transfected with TLR4 by LPS 100 ng/ml (1),
10 ng/ml (2), 1 ng/ml (3), 0.1 ng/ml (4); by affinity-purified anti-celiac
peptide antibodies, 4 lg/ml (5), 2 lg/ml (6), 1 lg/ml (7), 0.5 lg/ml (8) by
affinity-purified antibodies directed against an irrelevant control peptide,
4 lg/ml (9), 2 lg/ml (10), 1 lg/ml (11), and 0.5 lg/ml (12).
(B) Stimulation of 293T cells transfected with TLR4 by LPS 100 ng/ml (1),
10 ng/ml (2), 1 ng/ml (3), 0.1 ng/ml (4), by affinity-purified antibodies
against an irrelevant peptide 1 lg/ml (5), by affinity-purified anti-celiac
peptide antibodies 1 lg/ml (6), by affinity-purified anti-celiac peptide
antibodies 1 lg/ml in the presence of 1 lg/ml anti-TLR4 monoclonal
antibody (7), by affinity-purified anti-celiac peptide antibodies 1 lg/ml in
the presence of 1 lg/ml celiac peptide (8), by affinity-purified anti-celiac
peptide antibodies 1 lg/ml in the presence of 1 lg/ml irrelevant control
peptide (9), by affinity-purified anti-celiac peptide antibodies 1 lg/ml in
the presence of 1 lg/ml recombinant human tTG (10), by affinity-purified
anti-VP-7 peptide antibodies 1 lg/ml (11), by affinity-purified anti-VP-7
peptide antibodies 1 lg/ml in the presence of 1 lg/ml VP-7 peptide (12),
by affinity-purified anti-VP-7 peptide antibodies 1 lg/ml in the presence
of 1 lg/ml celiac peptide (13), and by affinity-purified anti-celiac peptide
antibodies 1 lg/ml in the presence of 1 lg/ml ovalbumin (14). Results
are expressed as percentage of positive control, where the positive
control is the OD value obtained upon stimulation of TLR4 transfected
cells with 100 ng/ml LPS (maximal concentration used).
DOI: 10.1371/journal.pmed.0030358.g007
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the VP-7 peptide and with pooled Igs from patients with
active disease and was similar to the permeability observed
after cell incubation with 250 U/ml TNF-alpha. This alter-
ation was present at a much lesser extent with pooled Igs
from patients on GFD (Figure 9B). The effect of affinity-
purified anti-celiac peptide antibodies on cell permeability
was blocked by pre-incubation of antibodies with human
recombinant tTG, celiac peptide, and recombinant desmo-
glein peptide but not by pre-incubation with the irrelevant
peptide (Figure 9C).
These data show that in CD there are antibodies able to
increase cell permeability upon interaction with junctional
proteins such as desmoglein 1.
Rabbit Antibodies Raised against the VP-7 Peptide
Activate TLR4 and Increase Epithelial Cell Permeability
The rabbit anti-VP-7 peptide antibodies were able to bind
human recombinant tTG and celiac, TLR4, and desmoglein 1
peptides (Figure 10A and 10B). Affinity-purified anti-VP-7
peptide antibodies were able to activate TLR4 in 293T cells
transfected with the TLR4 gene (Figure 10C). Moreover, such
antibodies were able to increase intestinal epithelial cell
permeability (Figure 10D).
These data further support the important role of the
rotavirus VP-7 epitope in CD.
Discussion
Our study aimed to clarify some aspects of the patho-
genesis of CD, a small intestinal inflammatory disorder
characterized by malabsorption, nutrient deficiency, and a
vast array of clinical manifestations. Many of the components
and events that generate the altered immune response to
gluten have been well characterized; however, there are some
features relevant to CD pathogenesis that are still unclear,
including the systemic autoimmune aggression, the role
played by infectious agents, and the involvement of innate
immunity in the different phases of the disease [10]. In our
attempt to answer these questions, we used a random peptide
library approach that we have already applied to the study of
other autoimmune disease conditions for the identification of
disease-relevant self-antigens [23–26]. Using this approach,
we identified a pathogenetically relevant autoantigen peptide
recognized by the sera of patients with active CD. Such
peptide shares homology with the rotavirus-derived protein
VP-7; human rotaviruses are the most frequent etiologic
agents of gastroenteritis in infants and young children in
most parts of the world [33]. Anti-celiac peptide antibodies
from patients with CD recognize the viral product, suggesting
a possible link between rotavirus infection and CD. Moreover,
anti-rotavirus IgG antibodies were detected in all patients
with CD and in only 32% of control participants, using
Western blot. Rotavirus infection has already been associated
with pancreatic islet autoimmunity through a mechanism of
molecular mimicry [34–36] between viral peptide sequences,
in particular within the VP-7 protein and T cell epitopes in
the islet cell autoantigen glutamate decarboxylase (GAD) and
tyrosine phosphatase IA-2 [37,38]. Moreover, immunization
of Lewis rats with a peptide derived from the rotavirus
protein VP4, showing homology with the highly pathogenic
peptide from retinal S-antigen, induced autoimmune uveitis
by triggering cross-reactive T cells [39].
We report here that purified anti-rotavirus VP-7 peptide
antibodies are able to cross-react with the celiac peptide,
desmoglein peptide, and TLR4 peptide. Moreover, such
antibodies bind endomysial structures and have functional
properties similar to the anti-celiac peptide antibody
Figure 8. Antibodies against the Celiac Peptide Recognize Desmoglein 1
(A) Sequence homology between the celiac peptide and cell junction
proteins. The peptide sequence was compared with known protein
sequences using the BLASTP via the NCBI BLAST network service (colons
indicate identity and asterisks indicate conservative substitutions).
(B) Sera of patients with active CD contain IgA antibodies directed
against desmoglein 1; such reactivity is not present in patients on GFD.
Recombinant desmoglein 1 was probed with antibodies affinity purified
against the celiac peptide (Lane 1), with antibodies affinity purified
against an irrelevant control peptide (Lane 2), with sera from patients
with active disease on GCD (Lanes 3 and 5), and with sera from the same
patients on GFD (Lanes 4 and 6). Biotin-labelled primary antibodies
followed by peroxidase-labelled avidin (Lanes 1 and 2) and an anti-
human IgA antibody (Lanes 3–6) were used for detection.
(C) The binding of affinity-purified anti-celiac peptide antibodies to solid-
phase desmoglein 1 is inhibited by desmoglein 1 (blue line), tTG (red
line), celiac peptide (purple line), VP-7 peptide (yellow line), and TLR4
peptide (green line), but not by the irrelevant control peptide (orange
line). The y-axis represents percentage of inhibition, and the x-axis
indicates inhibitor concentration (lg/ml).
DOI: 10.1371/journal.pmed.0030358.g008
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preparation because they activate TLR4 and alter cell
permeability. Finally, we have also observed that in patients
with CD the frequency of IgG and IgA antibodies against the
VP-7 peptide is higher than the frequency of antibodies
directed against the celiac peptide. Altogether, these data
suggest that an anti-rotavirus antibody response is present in
celiac patients mainly directed against an epitope within the
VP-7 protein. Such response occurs at high frequency when
compared with the response towards the celiac peptide, and,
therefore, since affinity-purified anti-VP-7 peptide antibodies
bind celiac peptide, recognize endomysial structures, activate
TLR4, and alter cell permeability, it suggests that the
rotavirus VP-7 epitope may be important in determining an
anti-virus immune response, able to cross-react with self-
antigens and to have functional consequences on TLR4
engagement and intestinal permeability. Therefore, it is likely
that a molecular mimicry mechanism may be involved in CD
pathogenesis.
The celiac peptide shares homology with tTG, the major
autoantigen target in CD; in particular, the homology
comprises the amino acid 476–487, an epitope located in
the immunodominant C-terminus area of tTG. Indeed, the
deletion of amino acid 476–496 has been reported to
completely abolish tTG binding by anti-tTG autoantibodies
in CD patients [31,40]. Therefore, with our approach we have
further restricted the immunodominant epitope to residues
476–487.
The celiac peptide also shares homology with other self-
antigens such as HSP60, MTMR2, and TLR4.
Heat-shock proteins are highly conserved proteins synthe-
sized when cells are exposed to stressful stimuli, such as
infection and inflammation [15], and increased expression of
HSPs has been observed in jejunal epithelial cells in patients
with CD [41]. Antibodies against the celiac peptide cross-react
with HSP60 and may therefore induce epithelial cell
cytotoxicity, thus amplifying the damage of the intestinal
mucosa with increased intestinal permeability. This is a key
feature of the disease and is also induced by the cross-reactive
anti-peptide antibodies.
MTMR2 belongs to the protein-tyrosine phosphatase
family. Defects in MPMR2 are the cause of Charcot-Marie-
Toot disease type 4, which is an autosomal recessive
demyelinating neuropathy [42]. A demyelinating nervous
system disease can be observed in patients with CD [20,21].
Finally, TLRs are type I transmembrane proteins involved
in innate immunity by recognition of conserved microbial
structures. Activation of antigen presenting cells via innate
immune receptors such as TLR4 can break self-tolerance and
trigger the development of autoimmunity [43,44]. The anti-
celiac peptide antibodies bind TLR4 on monocytes and
induce both the expression of activation molecules such as
CD83 and CD40 and the production of pro-inflammatory
cytokines in a extent similar to LPS. The cytokine secretion is
consequent to engagement of TLR4 because the pre-
incubation of monocytes with an anti-TLR4 monoclonal
antibody abolishes such production.
In conclusion, our data indicate that in active CD,
autoantibodies against an epitope of tTG bind other self-
antigens and the rotavirus-derived protein VP-7, suggesting a
viral involvement in the pathogenesis of the disease through a
mechanism of molecular mimicry. Moreover, such self-
reactive antibodies are pathogenetically relevant for their
Figure. 9. Anti-Celiac Peptide Antibodies Increase Epithelial Cell
Permeability
Cumulative [3H] mannitol flux following treatment with pooled anti-
bodies against the celiac peptide (n) or against the control peptide (¤)
purified from ten patients. Purified antibodies were applied to T84 cells
in the presence of [3H] mannitol (5 lCi/ml) in the basolateral compart-
ment. Apical buffer was sampled every 30 min over 6 h. * indicates
statistically significant difference in mannitol flux at 3 h (p¼ 0.01) and at
5 h (p ¼ 0.004). Representative example of three independently
performed experiments.
(B) Confluent T84 monolayers were treated for 3 h with pooled Igs from
healthy individuals (1), affinity-purified antibodies against the control
peptide from five patients (2), pooled antibodies affinity purified against
the celiac peptide from ten patients (3), pooled antibodies affinity
purified against tTG and negative for anti-desmoglein 1 activity from five
patients (4), pooled antibodies affinity purified against the desmoglein
peptide from five patients (5), pooled antibodies affinity purified against
the VP-7 peptide from ten patients (6), pooled antibodies affinity purified
against the TLR4 peptide from seven patients (7), pooled Igs from the 22
patients with active CD (8), pooled Igs from the same patients on GFD
(9), and TNF-alpha (250 U/ml) (10).
(C) Confluent T84 monolayers were treated for 3 h with pooled Igs from
healthy individuals (1), affinity-purified antibodies against the control
peptide (2), antibodies affinity purified against the celiac peptide (3), and
antibodies affinity purified against the celiac peptide in the presence of:
human recombinant tTG (4), celiac peptide (5), recombinant desmoglein
(6), and an irrelevant peptide (7). Data are mean percentages of control
(untreated sample) 6SD. n¼ 6 in duplicates.
DOI: 10.1371/journal.pmed.0030358.g009
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ability to alter the intestinal barrier integrity and to activate
monocytes. Monocyte activation follows the binding of TLR4,
providing a previously unknown mechanism for TLR4
stimulation. These results provide evidence for a link between
innate and adaptive immune response in the pathogenesis of
CD.
Supporting Information
Alternative Language Abstract S1. Italian Translation of the Abstract
Found at DOI: 10.1371/journal.pmed.0030358.sd001 (21 KB DOC).
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Editors’ Summary
Background. Celiac disease is an autoimmune, digestive disorder in
which the small intestine (the part of the gut that absorbs nutrients from
food) is damaged. In autoimmune diseases, the immune system, which
normally provides protection against foreign invaders, attacks a person’s
own tissues. In celiac disease, this attack is triggered by eating food
containing gluten, a mixture of proteins found in wheat, barley, and rye.
To avoid malnutrition, people with celiac disease—about one in 100
people of north European descent—must follow a strict, lifelong gluten-
free diet, one that avoids baked products, wheat, pasta, and many other
foods. If they fail to do this, their immune system may attack not only
their gut but also their brain, skin, joints, and other tissues, in part
through the production of antibodies (autoantibodies) that recognize a
protein (self-antigen) called tissue transglutaminase. Celiac disease is
diagnosed also by looking for these autoantibodies in patients’ blood
when they are on a gluten-containing diet; they rapidly disappear when
a gluten-free diet is adopted.
Why Was This Study Done? A gluten-free diet keeps celiac disease in
check but does not cure it and is very difficult to follow. Even the minute
amounts of gluten found in medicines, for example, can trigger the
production of autoantibodies and active disease. But developing a cure
is impossible without a better understanding of how celiac disease
develops. Why, for example, do celiac disease patients make anti-
transglutaminase antibodies? Were they made initially to ward off an
infectious agent but unfortunately also recognized transglutaminase? In
this study, the researchers asked whether ‘‘molecular mimicry’’—cross-
reactivity between self-molecules and foreign molecules on bacteria or
viruses (pathogens)—might initiate celiac disease. They also asked
whether innate immunity (the part of the immune system that responds
quickly to general features on pathogens) as well as adaptive immunity
(the production of antibodies and immune cells that recognize specific
features on pathogens) is involved in the development of celiac disease.
What Did the Researchers Do and Find? The researchers purified
antibodies from blood provided by patients with celiac disease when
they were eating food containing gluten and when they were on a
gluten-free diet. They used these to identify celiac peptide, a synthetic
protein fragment that was recognized only by the antibodies made by
patients with active disease. By searching a database of pathogen
proteins, the researchers discovered that rotavirus protein VP-7 contains
a very similar peptide; a search of a database of human proteins
indicated that celiac peptide also resembles peptides found in tissue
transglutaminase, Toll-like receptor 4 (TLR4; a protein involved in the
innate immune response), and several other self-antigens. Patient
antibodies purified through their ability to bind to celiac peptide also
bound to VP-7 and to these self-antigens, and only patients with active
disease made these antibodies. The researchers also investigated
whether these anti-celiac peptide antibodies might affect the gut or
the innate immune system. The antibodies increased the permeability of
a layer of gut cells growing in a laboratory dish by interacting with the
self-antigen desmoglein 1. This protein helps to make impermeable seals
between the cells that line the gut so that food antigens in the gut
cannot seep out into the tissues where the immune system might detect
them. In addition, by binding to TLR4, the anti-celiac peptide antibodies
activated monocytes—cells that function in both the innate and
adaptive immune response.
What Do These Findings Mean? The finding that some anti-trans-
glutaminase antibodies recognize the viral protein VP-7 could mean that
rotavirus infection, which causes gastroenteritis, helps to initiate celiac
disease in susceptible individuals through molecular mimicry. Further-
more, the identification of other self-antigens that contain peptides
recognized by the antibodies made during active disease starts to
explain why damage occurs outside the gut in people with celiac
disease. The ability of these antibodies to recognize all these peptides
could be coincidental, but the observation that the antibodies have
relevant functional effects—the ability to increase intestinal permeability
and to activate monocytes—makes this less likely. More research is
needed to reveal exactly how infections and the innate immune
response affect the development of celiac disease, but every piece of
new information brings the possibility of a cure a little closer.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030358.
 US National Institute of Diabetes and Digestive and Kidney Diseases,
information for patients on celiac disease
 MedlinePlus encyclopedia entries on celiac disease and on
autoimmunity
 Wikipedia pages on celiac disease and on autoimmunity (note that
Wikipedia is a free online encyclopedia that anyone can edit)
PLoS Medicine | www.plosmedicine.org September 2006 | Volume 3 | Issue 9 | e3581653
Innate Immunity in Celiac Disease
